Celldex Announces Planned Transition of Chief Financial Officer
Rhea-AI Summary
Celldex (NASDAQ:CLDX) announced that Senior Vice President and Chief Financial Officer Sam Martin plans to retire in 2027. Martin, CFO since 2017 and with Celldex since 2009, will remain in his role through March 2027 while the company conducts a CFO search.
According to Celldex, Martin has helped guide its evolution toward a late-stage immunology company. The company highlights a robust pipeline and notes that key data from two Phase 3 barzolvolimab trials are expected later in 2026.
Positive
- Orderly CFO transition with Sam Martin remaining through March 2027
- Long-tenured finance leadership since 2009 supports continuity during succession
- Company cites a robust pipeline and two Phase 3 barzolvolimab trials with data expected later in 2026
Negative
- Planned retirement of long-serving CFO introduces leadership transition in 2027
News Market Reaction – CLDX
In the Jul 16 session, CLDX declined 7.60%, reflecting a notable negative market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | pipeline presentations | Positive | +2.1% | New data presentations on mast cell–targeting pipeline at EAACI 2026. |
| May 07 | earnings and update | Positive | +1.9% | Q1 2026 results with early Phase 3 enrollment completion and financing. |
| Apr 13 | investor conference | Positive | +2.3% | Management participation in inflammatory skin disease investor conference webcast. |
| Apr 06 | offering close | Negative | +1.0% | Closing of underwritten public offering and full exercise of option. |
| Apr 01 | offering pricing | Negative | -0.6% | Pricing of $300M underwritten common stock offering for barzolvolimab plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CLDX news has generally been followed by modestly positive next-day moves, including pipeline and financing updates, with one divergence around an offering close.
Key Terms
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company’s Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and Mr. Martin will remain as the Company’s CFO through March of 2027, to support a smooth transition.
“We are grateful to Sam for his strong contributions over many years of service to Celldex and wish him the very best in his retirement,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. “Sam has played an important role in Celldex’s growth from an emerging early-stage R&D company to a late-stage leading immunology company, leading a very successful finance organization that will continue to support our work towards building a fully integrated commercial company.”
“I am proud of what we have accomplished at Celldex and honored to have worked with such a talented team,” said Sam Martin, Senior Vice President and Chief Financial Officer at Celldex. “With a robust pipeline in development, a continued focus on growing commercial capabilities and important data readouts from two Phase 3 barzolvolimab trials expected later this year, I am excited about the future of the company and confident that it is well positioned for success.”
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Elizabeth Higgins
Executive Director, Investor Relations & Corporate Communications
(857) 404-2088
ehiggins@celldex.com
